# Paean Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/paean-biotechnology

- Industry: Biotechnology
- Headquarters: Daejeon, South Korea
- Website: www.paeanbio.com/
- Total disclosed funding: $5.1M
- Latest round: Series A (Jul 8, 2019)
- Investors on record: 3

## About

Paean Biotechnology, based in Daejeon, South Korea, focuses on the development of mitochondria-based therapeutics to address rare diseases and cancer, positioning itself as a key player in biopharmaceutical innovation.Founded in 2013 in Daejeon, South Korea, Paean Biotechnology specializes in mitochondrial therapies. The company has engaged in 3 deals, with its most recent funding round occurring in January 2021. In this round, Paean Biotechnology raised KRW 4.5 billion from investors including Hana Ventures and Korea Investment Partners. The founder's background is not publicly detailed, nor does the company have known subsidiaries. Paean Biotechnology specializes in mitochondria-based therapeutics, positioning itself as a leader in the development of biopharmaceutical agents that utilize modified mitochondria to address rare diseases and cancer. Their core product offerings include MitoTherapy and Mitoceuticals. MitoTherapy products are designed to enhance cellular function and energy production through the application of allogenic mitochondria, while Mitoceuticals focus on modified formulations that aim to improve overall mitochondrial health. These products primarily serve healthcare providers and research institutions in various international markets, including South Korea and regions in Europe, where they are positioned to support clinical applications and research initiatives. The company’s innovative use of proprietary technology for isolating, storing, and modifying mitochondria marks a significant advancement in therapeutic options for patients suffering from debilitating conditions. Paean Biotechnology's revenue generation model is anchored in strategic partnerships, research collaborations, and clinical trial funding. The company engages in B2B transactions with healthcare providers and research institutions, facilitating access to their flagship products, MitoTherapy and Mitoceuticals. Revenue is generated through funding rounds, including pre-Series A and Series A and B funding, as well as ongoing collaboration agreements, which involve milestone payments based on clinical trial advancements and regulatory approvals. Specific pricing plans for products and services are tailored to the needs of clinical partners and may involve negotiated rates for bulk access or exclusive rights to product offerings. Overall, the structured transaction model leverages collaborations that enhance the reach and application of Paean Biotechnology's innovative mitochondrial therapies. Paean Biotechnology is actively pursuing the development of new mitochondrial-based therapeutic products, with a focus on launching these innovations in the upcoming years. The company aims to expand its market presence primarily in Europe and North America by 2023. The KRW 4.5 billion raised in early 2021 will be utilized to support these product developments and market entries, enhancing their capabilities in addressing unmet medical needs in the field of rare diseases and cancer.

## Funding rounds

- Series A, Jul 8, 2019, $5.1M — Korea Investment Partners, Timefolio Asset Management, Hana Ventures

## Investors

- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Series A
- Timefolio Asset Management — Series A
- Hana Ventures — Series A